Exchange Traded Concepts LLC boosted its holdings in Xencor, Inc. (NASDAQ:XNCR – Free Report) by 23.9% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 9,814 shares of the biopharmaceutical company’s stock after buying an additional 1,896 shares during the quarter. Exchange Traded Concepts LLC’s holdings in Xencor were worth $104,000 as of its most recent SEC filing.
Other hedge funds have also recently added to or reduced their stakes in the company. Sterling Capital Management LLC boosted its stake in shares of Xencor by 732.4% during the 4th quarter. Sterling Capital Management LLC now owns 1,182 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 1,040 shares during the period. GF Fund Management CO. LTD. acquired a new stake in shares of Xencor during the 4th quarter valued at $34,000. PNC Financial Services Group Inc. boosted its stake in shares of Xencor by 49.4% during the 4th quarter. PNC Financial Services Group Inc. now owns 4,041 shares of the biopharmaceutical company’s stock valued at $93,000 after buying an additional 1,337 shares during the period. Mackenzie Financial Corp acquired a new stake in shares of Xencor during the 4th quarter valued at $101,000. Finally, GAMMA Investing LLC boosted its stake in shares of Xencor by 348.5% during the 1st quarter. GAMMA Investing LLC now owns 9,629 shares of the biopharmaceutical company’s stock valued at $102,000 after buying an additional 7,482 shares during the period.
Xencor Stock Performance
NASDAQ XNCR opened at $8.27 on Wednesday. The stock has a market cap of $588.58 million, a P/E ratio of -2.70 and a beta of 0.87. The company’s 50-day simple moving average is $9.04 and its 200 day simple moving average is $14.26. Xencor, Inc. has a twelve month low of $7.16 and a twelve month high of $27.24. The company has a quick ratio of 5.89, a current ratio of 5.89 and a debt-to-equity ratio of 0.16.
Insider Transactions at Xencor
In related news, Director Kurt A. Gustafson sold 2,993 shares of the stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $9.22, for a total value of $27,595.46. Following the transaction, the director now directly owns 20,183 shares in the company, valued at $186,087.26. This represents a 12.91% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Nancy Valente sold 4,616 shares of the company’s stock in a transaction that occurred on Friday, May 2nd. The shares were sold at an average price of $11.03, for a total transaction of $50,914.48. Following the completion of the sale, the executive vice president now directly owns 49,169 shares of the company’s stock, valued at $542,334.07. The trade was a 8.58% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 15,810 shares of company stock worth $154,123. Corporate insiders own 5.23% of the company’s stock.
Wall Street Analyst Weigh In
A number of brokerages have issued reports on XNCR. Wedbush reissued an “outperform” rating and set a $31.00 target price on shares of Xencor in a research note on Wednesday, April 30th. William Blair began coverage on shares of Xencor in a research report on Monday, April 21st. They set an “outperform” rating for the company. Wells Fargo & Company cut their target price on shares of Xencor from $37.00 to $33.00 and set an “overweight” rating for the company in a research report on Friday, February 28th. Wall Street Zen lowered shares of Xencor from a “hold” rating to a “sell” rating in a research report on Friday, March 14th. Finally, Barclays cut their target price on shares of Xencor from $22.00 to $6.00 and set an “underweight” rating for the company in a research report on Thursday, May 8th. Two research analysts have rated the stock with a sell rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, Xencor currently has an average rating of “Moderate Buy” and an average target price of $28.00.
Read Our Latest Report on Xencor
Xencor Profile
Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.
Featured Stories
- Five stocks we like better than Xencor
- What is Insider Trading? What You Can Learn from Insider Trading
- 3 Hot Trades for Insiders, But Are They Good Buys for Investors?
- What Are Trending Stocks? Trending Stocks Explained
- Why Qualcomm’s Latest Price Target Can’t Be Ignored
- A Deeper Look at Bid-Ask Spreads
- Analyst Sees Meta Hitting $800: What May Lead Shares to New Highs
Want to see what other hedge funds are holding XNCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xencor, Inc. (NASDAQ:XNCR – Free Report).
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.